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ABSTRACT
Amicrobial pustulosis of the folds is a rare neutrophilic dermatosis, co-existing with autoimmune disorders, especially with systemic lupus 
erythaematosus. The disease is characterised by the presence of sterile pustules localised in the skin folds, intraepidermal pustules with 
mainly neutrophilic infiltrate on histology, negative microbial cultures from an unopened pustule and the presence of circulating autoan-
tibodies or autoinflammatory diseases. Due to its rare incidence, data on effective therapeutic options are limited to individual clinical 
cases. We present a 69-year-old man with disseminated pustular lesions in the main skin folds, focusing on the clinical, histopathological 
and immunological characteristics of the disease. Based on the clinical presentation and laboratory investigation, amicrobial pustulosis of 
the folds was diagnosed with an accompanying increased concentration of anti-thyreoperoxidase antibodies with compensated thyroid 
hormones. After two weeks of the treatment with local glucocorticosteroids, skin lesions disappeared, leaving the post-inflammatory 
discoloration. The patient remains without recurrence of any skin lesions during the five-month observation period.
To conclude, in the diagnosis of this rare disease, the clinicopathological correlation plays a crucial role, as well as the investigation for 
the co-existing autoimmune disorders.
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STRESZCZENIE
Amicrobial pustulosis of the folds (APF) jest rzadką dermatozą neutrofilową, współistniejącą z zaburzeniami autoimmunologicznymi, 
zwłaszcza toczniem rumieniowatym układowym. Choroba charakteryzuje się obecnością: 1. jałowych śródnaskórkowych krost zlokalizo-
wanych w fałdach skórnych, 2. odczynów zapalnych neutrofilowych w skórze właściwej, przy negatywnych posiewach mikrobiologicznych 
oraz 3. obecnością krążących autoprzeciwciał lub współistnieniem chorób autozapalnych. W związku z rzadkim występowaniem, dane 
dotyczące skutecznych opcji terapeutycznych ograniczają się do opisów pojedynczych przypadków klinicznych.
Prezentujemy przypadek 69-letniego mężczyzny z rozsianymi zmianami krostkowymi w fałdach i ich otoczeniu, skupiając się na obra-
zie klinicznym, histopatologicznym oraz immunologicznym choroby. Na podstawie wykonanych badań, w oparciu o obraz kliniczny, 
u pacjenta rozpoznano amicrobial pustulosis of the folds z towarzyszącym wzrostem stężenia przeciwciał przeciwko tyreoperoksydazie, 
przy wyrównanych hormonach tarczycy. 
Po dwutygodniowej terapii miejscowymi glikokortykosteroidami uzyskano ustąpienie zmian skórnych, z pozostawieniem przebarwień 
pozapalnych. Pacjent pozostaje w remisji w trakcie 5-miesięcznego okresu obserwacji.
W podsumowaniu, w rozpoznaniu tej rzadkiej jednostki chorobowej dużą rolę odgrywa korelacja kliniczno-patologiczna i poszukiwanie 
współistniejących zaburzeń autoimmunologicznych.
Forum Derm. 2018; 4, 1: 5–9
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INTRODUCTION
Amicrobial pustulosis of the folds is a rare clinical con-
dition, which has been reported in association with au-
toimmune diseases and is classified within the spectrum 
of neutrophilic dermatoses. It is characterised by the re-
lapsing pustular lesions consisting of small follicular and 
non-follicular sterile pustules, usually grouped on inflam-
matory, erythaematous plaques and involving mainly the 
cutaneous folds, anogenital region and scalp. The course 
is often chronic, with relapses. Its underlying pathogenic 
mechanism remains controversial [1–3].
We present a case of 69-year-old man with hypertension 
and asthma, who presented to our department with a three-
week history of escalating pustular eruption of major skin 
folds with co-existing pruritus. The patient presented diffuse 
pustular lesions in axillary and mammary regions (Fig. 1), 
anogenital area (mainly scrotum and inguinal folds), as well 
as the posterior neck. The pustules were well demarcated, 
unrelated to hair follicles, arising on the erythaematous 
skin background. In addition, erosions (partially covered 
with haemorrhagic crusts) and inflammatory papules were 
observed. The appearance of lesions was not preceded by 
any infection or new medication taken. Before, due to the 
suspicion of disseminated herpes zoster, the lesions were 
treated with acyclovir without significant improvement.
Histopathological examination of the biopsy taken from 
the lesion of the arm pit showed the presence of subcorneal 
pustules, psoriasiform epidermal hyperplasia with granular 
layer preserved, as well as dilatation and congestion of the 
dermal papillae (Fig. 2). Periodic Acid-Schiff (PAS) staining 
of the biopsy specimen gave a negative result. Histological 
findings in correlation with clinical presentation suggested 
the diagnosis of amicrobial pustulosis of the folds (APF).
In order to verify the diagnosis, a number of additional 
tests were performed. Tissue examination of the healthy 
looking skin surrounding the lesion gave a negative result 
for IgG, IgA, IgM and complement component C3 in the 
direct immunofluorescence (DIF) method. Analysis of the 
blood serum by the means of indirect immunofluorescence 
(IIF) did not show evidence of antinuclear, anticardiolipin 
or antineutrophil cytoplasmic antibodies. The laboratory 
results, including full blood cell count, electrolytes, glycae-
mia, renal and hepatic function and tumour markers were 
within normal limits. The only abnormality in the routine 
laboratory tests was an increased concentration of antibod-
ies against thyreoperoxidase (ATPO; 48 IU/mL; laboratory 
standard: < 9 IU/mL) without any thyroid hormones distur-
bances (TSH 1.61 mcIU/mL; fT3 3.11 pg/mL, fT4 0.92 ng/dL). 
There were no clinical symptoms of autoimmune thyroiditis 
observed.
Based on the clinical and histopathological findings, 
the patient was diagnosed with APF. An improvement lead-
Figure 1. The patient presented diffuse pustular lesions in axillary 
and mammary regions as presented on the picture
Figure 2. Histopathologic features detected with haematoxylin-eosin 
stain (H&E). A. Psoriasiform epidermal hyperplasia with granular layer 
preserved, intracorneal neutrophilic large pustule not associated 
with hair follicle, papillary dermal oedema with inflammatory 
perivascular inflammation are visible (H&E, 100×). B. Magnified 
intracorneal neutrophilic pustule with preserved granular layer below 
in an hyperplastic, psoriasiform epidermis (H&E, 400×) 
A
B
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glucocorticosteroids (betamethasone dipropionate, flut-
icasone propionate) twice a day and oral bilastine. After 
the treatment, only post-inflammatory discoloration was 
observed (Fig. 3). Currently, during the five-month obser-
vation, the patient remains without recurrence of any skin 
lesions. Control laboratory tests revealed, however, even 
higher ATPO antibodies concentration of 59,70 IU/ml, as well 
as elevation of fT3 concentration (4.27 pg/mL; laboratory 
standard: 2.5–3.9 pg/mL) and stable fT4 and TSH (0.83 ng/dL 
and 2.38 mcIU/mL respectively). The patient still did not 
manifest any signs of thyroiditis. Further endocrinological 
care, as well as thyroid ultrasonography was recommended.
The disease was first reported in 1991 by Crickx and 
colleagues [4] in two young women with systemic lupus 
erythaematosus (SLE) and outbreaks of amicrobial pus-
tules. Since its first description, over 60 cases have been 
described in the literature, with only 10% of them affecting 
men and mostly involving young population (mean age, 
30 years). The patients with APF exhibit a wide spectrum of 
autoimmune abnormalities. Whilst the SLE co-occurrence is 
the most common among the autoimmune diseases associ-
ated with APF (27%), over one third of all the cases involves 
antinuclear antibodies (ANA) or soluble extractable nuclear 
antibodies (ENA) with no autoimmune disease established. 
There are also several cases concerning Sharp’s syndrome, 
Sjoegren’s syndrome or Crohn’s disease, as well as single 
reports on various autoimmune diseases co-existence [2]. 
Reports showing an association between the thyroid disease 
and pustular and neutrophilic dermatoses are rare. There 
were reports of five cases revealing APF in the course of 
thyroiditis so far [5–7]. Our case is, to our knowledge, the 
second one reported with no ANA or ENA and the first one 
in a male patient. The characteristics of APF with co-existing 
thyroiditis cases are presented in Table 1. Further studies are 
needed to clarify the pathways responsible for the patho-
genesis of APF in association with both thyroid disease and 
other autoimmune diseases. High levels of IL-1α, IL-1β and 
IL-17 were detected in the skin lesions of APF [8].
Our patient had characteristic clinical and histopatho-
logical features of APF, with erosive areas surrounded by 
isolated pustules and papules. Typical histological features 
involve subcorneal and intraepidermal spongiform pustules 
in an acanthotic epidermis and a dermal inflammatory in-
filtrate, predominantly consisting of neutrophils, without 
vasculitis. In older plaques, psoriasiform hyperplasia with 
parakeratosis is observed. Direct immunofluorescence stud-
ies including the lupus band test are usually negative [1–3].
As the disease shares common clinical and histopatho-
logical features with other pustular dermatoses, differen-
tial diagnosis might be problematic. The following entities 
should be taken into consideration while differentiating 
the condition: pustular psoriasis, mainly its inverse type 
Figure 3. Resolution of pustular lesions with post-inflammatory 
discoloration involving intertriginous and extra-intertriginous 
anatomical locations. A. Chest and neck. B. Nape. C. Groin
 
ing to resolution of almost all cutaneous lesions was ob-
served after two-week treatment with high-potency topical 
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B
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(minor folds involvement is less characteristic; usually the 
presence of psoriatic lesions outside the skin folds), Sned-
don-Wilkinson disease (different course of the disease, 
higher mean age of the patients, characteristic appear-
ance of the pustules: half-and-half blisters, fine scaling af-
ter relapse, less characteristic psoriasis-like appearance of 
epidermis in histopathology), pemphigus foliaceus (posi-
tive DIF), IgA pemphigus (intraepidermal IgA deposits in 
DIF), acute gene ralised exanthaematous pustulosis (more 
severe course of the disease), impetigo herpetiformis and 
bacterial and candidal dermatoses [2–3]. Clinicopathologic 
correlation plays an important role, that is why Marzano et 
al. [1] in 2008 proposed some diagnostic criteria providing 
both for clinical manifestations of the disease (pustulosis 
affecting one or more major folds; aseptic pustules), histolo - 
gical pattern (intraepidermal spongiform pustulosis with 
neutrophil infiltrate in the dermis) — obligate criteria; as 
well as immunological deviations (so called ‘minor criteria’: 
the association with one or more autoimmune disorders, 
ANA titters of 1:160 or more, or the presence of additional 
autoantibodies).
The therapy of APF is not well standardised. Due to 
low incidence of APF, data on effective therapeutic options 
are limited to solitary cases. Several cases of topical cor-
ticosteroids clinical effectiveness in monotherapy in APF 
have been described to date [9–10]. In most cases however, 
systemic treatment was utilised, with oral corticosteroids 
(0.5–1 mg/kg/day of prednisone dose equivalent) given 
in most cases in monotherapy or in combination [2]. In 
individual cases, cyclosporine A and dapsone, hydroxychlo-
roquine, and methotrexate have successfully been used in 
addition to systemic corticosteroids. There are also some 
reports on good response to colchicine, as well as healing 
with zinc and ascorbic acid supplementation [3]. In more 
resistant cases, cytokine inhibitors such as anakinra, infli - 
ximab and ustekinumab might be useful, as their effica-
cy was recently shown in a couple of cases [3, 10, 11]. We 
obtained a complete response without noticeable relapse 
lasting 5 months of follow-up, until the time of writing. 
Relapses of APF following tapering or discontinuation of 
treatment are common. However, long-term remissions of 
the disease have been reported only rarely [12].
In conclusion, amicrobial pustulosis of the folds is 
a rare neutrophil dermatosis, co-existing with autoimmune 
dis orders. The diagnosis of this entity can be difficult and 
it should always be taken into consideration in cases of 
neutrophillic infiltrate of the skin. Most importantly, a clin-
icopathological correlation plays a crucial role in making 
an accurate diagnosis. Finally, as most cases of APF are as-
sociated with other diseases, screening and monitoring 
particularly for autoimmune diseases is necessary. We con-
sider taking into account the possibility of asymptomatic 
autoimmune thyroiditis co-existence, as it was in case of 
our patient and another one described previously [6]. The 
cases of such subclinical immunological disturbances need 
further monitoring, even though they might not evolve into 
treatment-requiring disease.
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